Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FYN | P06241 | 16/20 | 0.71 |
| ▸ | DYRK3 | O43781 | 3/20 | 0.67 |
| ▸ | CCNT1 | O60563 | 3/20 | 0.67 |
| ▸ | CCNA2 | P20248 | 3/20 | 0.67 |
| ▸ | CDK2 | P24941 | 3/20 | 0.67 |
| ▸ | CDK9 | P50750 | 3/20 | 0.67 |
| ▸ | CDK5 | Q00535 | 3/20 | 0.67 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.67 |
| ▸ | CDK5R1 | Q15078 | 3/20 | 0.67 |
| ▸ | DYRK2 | Q92630 | 3/20 | 0.67 |
| ▸ | DYRK1B | Q9Y463 | 3/20 | 0.67 |
| ▸ | CLK1 | P49759 | 1/20 | 0.61 |
| ▸ | CLK2 | P49760 | 1/20 | 0.61 |
| ▸ | CLK3 | P49761 | 1/20 | 0.61 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.61 |
| ▸ | PIM1 | P11309 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4691093 | 0.89 | FYN (0.71) | FYNPIM1 | |
| SCHEMBL2943321 | 0.83 | FYN (1.00) | FYNDYRK3CCNT1CCNA2CDK2 | |
| SCHEMBL2942616 | 0.83 | PIM1 (0.76) | FYNPIM1 | |
| SCHEMBL1945307 | 0.83 | FYN (0.71) | FYN | |
| SCHEMBL1055826 | 0.83 | FYN (0.79) | FYNDYRK3CCNT1CCNA2CDK2 | |
| SCHEMBL2951889 | 0.83 | FYN (0.63) | FYNPIM1 | |
| SCHEMBL2944095 | 0.82 | FYN (0.80) | FYNDYRK3CCNT1CCNA2CDK2 | |
| SCHEMBL13234281 | 0.82 | FYN (0.71) | FYNDYRK3CCNT1CCNA2CDK2 | |
| SCHEMBL13223333 | 0.82 | MKNK1 (0.67) | FYNDYRK3CCNT1CCNA2CDK2 | |
| SCHEMBL18613397 | 0.82 | FYN (1.00) | FYNDYRK3CCNT1CCNA2CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9458463-B2 | Method for treatment of diabetes by a small molecule inhibitor for GRK5 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2016-10-04 | — | — | US | claimed |
| EP-2818471-A1 | Nitrogen bicyclic compounds as inhibitors for Scyl1 and Grk5 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2014-12-31 | — | — | EP | claimed |
| US-9458463-B2 | Method for treatment of diabetes by a small molecule inhibitor for GRK5 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2016-10-04 | — | — | US | disclosed |
| US-20150079108-A1 | KINASES AS TARGETS FOR ANTI-DIABETIC THERAPY | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2015-03-19 | — | — | US | disclosed |
| EP-2818471-A1 | Nitrogen bicyclic compounds as inhibitors for Scyl1 and Grk5 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2014-12-31 | — | — | EP | disclosed |
| US-7750000-B2 | Substituted imidazo[1,2b]pyridazines as kinase inhibitors, their preparation and use as medicaments | BAYER SCHERING PHARMA AG (DE) | 2010-07-06 | — | — | US | disclosed |
| US-7750000-B2 | Substituted imidazo[1,2b]pyridazines as kinase inhibitors, their preparation and use as medicaments | BAYER SCHERING PHARMA AG (DE) | 2010-07-06 | — | — | US | disclosed |
| US-7750000-B2 | Substituted imidazo[1,2b]pyridazines as kinase inhibitors, their preparation and use as medicaments | BAYER SCHERING PHARMA AG (DE) | 2010-07-06 | — | — | US | disclosed |
| US-20070093490-A1 | Substituted imidazo[1,2b]pyridazines as kinase inhibitors, their preparation and use as medicaments | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2007-04-26 | — | — | US | disclosed |
| US-20070093490-A1 | Substituted imidazo[1,2b]pyridazines as kinase inhibitors, their preparation and use as medicaments | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2007-04-26 | — | — | US | disclosed |
| US-20070093490-A1 | Substituted imidazo[1,2b]pyridazines as kinase inhibitors, their preparation and use as medicaments | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2007-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150079108-A1 | KINASES AS TARGETS FOR ANTI-DIABETIC THERAPY | GCKR, GRK4, GRK5 | FYN 574/4885DYRK3 590/4885CCNT1 3376/4885 |
| US-20070093490-A1 | Substituted imidazo[1,2b]pyridazines as kinase inhibitors, their preparation and use as medicaments | MAP4K2, MAP3K1, MAP3K2 | FYN 421/4885DYRK3 539/4885CCNT1 773/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.